Replies to post #279290 on Avid Bioservices Inc (CDMO)

[goodJohnhunting]

Again not a scientist but please elaborate as to where this was proven...

"when the data mining proved that binding is unstable, unpredictable, and subject to unsubscribed variances"

"Unstable" as in from person to person, IMO

"Unstable" as in the amount of antiPs administered. Remember, "higher volume" antiPS antibody in the blood stream correlates to lower available b2gp1 to bind. This is the curve of diminishing returns, as related to b2gp1 and availability, IMO.

"Unpredictable" as in undefined parameters regarding cohorts in Sunrise trial. For example, what diet, drug use, age, weight, metabolic readings etc, contributed to B2GP1 levels?

Regarding "drug use", I believe that there is a direct link between B2GP1 levels and statin use, either prior to Sunrise, or during the trial.

"Unknown variances" as in 200/240 range, but what is known about the readings above and below this threshold?

How many twotonelephants does that make?. And what about "cross reactivity of PS and B2GP1.?? Do these contribute to binding "unpredictability", "Instability", "Unknown variances" and Bavituximab's MOA, efficacy etc..

All the best,
John

[goodJohnhunting]

Jake,

Again not a scientist but please elaborate as to where this was proven...

The data mining proved that 70% of administered Bavituximab didn't bind, if we trust the 200/240 B2GP1 and 30% stat sig statement from Peregrine. The remaining cohorts scored less than placebo in the trial, if we trust what was presented at ESMO. The data mining is telling us that binding is an issue. Not me.

All the best,
John